A detailed history of Pnc Financial Services Group, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 6,289 shares of VIR stock, worth $46,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,289
Previous 9,719 35.29%
Holding current value
$46,538
Previous $86,000 45.35%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$7.26 - $10.7 $24,901 - $36,701
-3,430 Reduced 35.29%
6,289 $47,000
Q2 2024

Aug 09, 2024

SELL
$7.63 - $12.66 $39,973 - $66,325
-5,239 Reduced 35.02%
9,719 $86,000
Q1 2024

May 10, 2024

BUY
$8.6 - $11.9 $32,439 - $44,886
3,772 Added 33.72%
14,958 $151,000
Q4 2023

Feb 09, 2024

BUY
$7.76 - $10.29 $14,503 - $19,232
1,869 Added 20.06%
11,186 $112,000
Q3 2023

Nov 13, 2023

BUY
$9.14 - $24.62 $42,555 - $114,630
4,656 Added 99.89%
9,317 $87,000
Q2 2023

Aug 11, 2023

BUY
$23.2 - $27.29 $14,848 - $17,465
640 Added 15.92%
4,661 $114,000
Q1 2023

May 15, 2023

BUY
$22.26 - $30.85 $289 - $401
13 Added 0.32%
4,021 $93,000
Q4 2022

Feb 10, 2023

BUY
$19.96 - $28.22 $58,622 - $82,882
2,937 Added 274.23%
4,008 $101,000
Q3 2022

Nov 10, 2022

SELL
$18.26 - $31.1 $61,390 - $104,558
-3,362 Reduced 75.84%
1,071 $20,000
Q2 2022

Aug 12, 2022

BUY
$19.08 - $26.7 $84,581 - $118,361
4,433 New
4,433 $112,000
Q4 2020

Feb 12, 2021

SELL
$25.51 - $43.38 $663 - $1,127
-26 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$28.28 - $53.6 $735 - $1,393
26 New
26 $0
Q2 2020

Aug 07, 2020

SELL
$27.89 - $47.86 $6,024 - $10,337
-216 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$12.04 - $60.2 $2,600 - $13,003
216 New
216 $7,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $982M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.